Evidence Level:Resistant: C3 – Early Trials
Title:
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer
Excerpt:The polymorphism 181946 C>T in the EGFR gene has also been investigated for gefitinib treatment....Two of three studies did find significant decreases in PFS and OS...
DOI:https://doi.org/10.1016/j.drup.2022.100832